Trial Profile
A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Erdafitinib (Primary) ; Docetaxel; Pembrolizumab; Vinflunine
- Indications Carcinoma; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms THOR
- Sponsors Janssen; Janssen Research & Development; Janssen-Cilag
- 24 Apr 2024 trial now transitioned in France, retained status as per NCT
- 26 Mar 2024 Planned primary completion date changed from 29 Feb 2024 to 11 Sep 2024.
- 27 Feb 2024 Planned End Date changed from 7 Aug 2024 to 11 Sep 2024.